Objectives: There is much controversy surrounding the diagnosis and treatment of patients with bipolar II disorder (BP II). To address the growing need to find effective treatment strategies for patients with BP II, this article identifies and summarizes available published evidence specific to the pharmacotherapy of BP II.

Methods: Using the keywords, 'bipolar disorder', 'type II' or 'type 2', 'bipolar II', 'hypomania', and 'bipolar spectrum', a search of the databases Medline (via PubMed), the Cochrane Central Register of Controlled Trials (via Ovid), and PsychInfo was conducted for the period January 1994 to January 2003. Articles deemed directly relevant to the treatment of BP II were selected. Studies that included both BP I and II patients were excluded if results for BP II patients were not analyzed and reported separately.

Results: Fourteen articles were selected for the review period. There are no double blind, randomized controlled trials (RCT) involving only BP II patients. Most studies investigating the pharmacotherapy of BP II are methodologically limited, having observational or retrospective designs and small samples. For long-term treatment, lamotrigine has the strongest quality of evidence (double blind RCT), while lithium is the best studied. With regard to short-term treatment, there is some limited support for the use of risperidone in hypomania, and for divalproex, fluoxetine and venlafaxine in treating depression.

Conclusions: There is a paucity of sound evidence to help guide clinicians treating BP II patients. Decisions about pharmacotherapy should be made on a case-by-case basis; overall, broad recommendations that are based on available evidence cannot be adequately made. More quality research is needed to delineate effective treatment strategies.

Download full-text PDF

Source
http://dx.doi.org/10.1046/j.1399-5618.2003.00086.xDOI Listing

Publication Analysis

Top Keywords

bipolar disorder
8
effective treatment
8
treatment strategies
8
controlled trials
8
double blind
8
treatment
6
patients
6
evidence
5
pharmacotherapy
4
pharmacotherapy bipolar
4

Similar Publications

Untangling the complex relationship between bipolar disorder and anxiety: a comprehensive review of prevalence, prognosis, and therapy.

J Neural Transm (Vienna)

January 2025

Laboratory of Biological Psychiatry, Institute of Mental Health, Tianjin Anding Hospital, Mental Health Center of Tianjin Medical University, 13 Liulin Road, Tianjin, 300222, China.

Bipolar disorder (BD) frequently coexists with anxiety disorders, creating complex challenges in clinical therapy and management. This study investigates the prevalence, prognostic implications, and treatment strategies for comorbid BD and anxiety disorders. High comorbidity rates, particularly with generalized anxiety disorder, underscore the necessity of thorough clinical assessments to guide effective management.

View Article and Find Full Text PDF

Identifying cell types and brain regions critical for psychiatric disorders and brain traits is essential for targeted neurobiological research. By integrating genomic insights from genome-wide association studies with a comprehensive single-cell transcriptomic atlas of the adult human brain, we prioritized specific neuronal clusters significantly enriched for the SNP-heritabilities for schizophrenia, bipolar disorder, and major depressive disorder along with intelligence, education, and neuroticism. Extrapolation of cell-type results to brain regions reveals the whole-brain impact of schizophrenia genetic risk, with subregions in the hippocampus and amygdala exhibiting the most significant enrichment of SNP-heritability.

View Article and Find Full Text PDF

High-order network degree revealed shared and distinct features among schizophrenia, bipolar disorder and ADHD.

Neuroscience

January 2025

School of Aerospace Engineering, Xi'an Jiaotong University, Xi'an, China; State Key Laboratory for Strength and Vibration of Mechanical Structures, Xi'an, China; National Demonstration Center for Experimental Mechanics Education, Xi'an Jiaotong University, Xi'an, China. Electronic address:

Schizophrenia (SCHZ), bipolar disorder (BD), and attention-deficit/hyperactivity disorder (ADHD) share clinical symptoms and risk genes, but the shared and distinct neural dynamic mechanisms remain inadequately understood. Degree is a fundamental and important graph measure in network neuroscience, and we here extended the degree to hierarchical levels based on eigenmodes and compared the resting-state brain networks of three disorders and healthy controls (HC). First, compared to HC, SCHZ and BD patients exhibited substantially overlapped abnormalities in brain networks, wherein BD patients displayed more significant alterations.

View Article and Find Full Text PDF

Mapping global evidence of caregiver experiences in bipolar disorder in low and middle-income countries: A scoping review.

J Affect Disord

January 2025

Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, Ontario, Canada; Department of Psychiatry, Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada.

Background: Bipolar disorder (BD) imposes significant social, psychological, and economic burdens on individuals and their caregivers. While developing treatments for BD patients is crucial, supportive interventions for caregivers in low- and middle-income countries (LMICs) are equally important, given the limited resources and healthcare infrastructure. Understanding caregiver experiences in these settings is essential for creating effective interventions.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!